| Description | Bretylium tosylate is an inhibitor of the presynaptic release of vasoconstrictor neurotransmitters, a available antiarrhythmic drug for ventricular arrhythmias. |
| In vivo | 九名患者在遭受急性心肌梗塞或心绞痛后出现反复心室颤动，经其他措施无效后，每八小时通过肌肉注射方式给予bretylium tosylate 5 mg./kg。只要患者未处于休克或心力衰竭状态，即可显著减少心室颤动发作次数。另一组九名患者在开心手术后发展为反复心室颤动，通过静脉给予bretylium，每次均能控制心律失常。Bretylium并未完全消除室性早搏，但即便室性早搏发生在T波[1]上，也未引发心室颤动。 |
| Synonyms | 溴苄乙胺, 托西溴苄铵 |
| molecular weight | 414.36 |
| Molecular formula | C18H24BrNO3S |
| CAS | 61-75-6 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility | DMSO: 30 mg/mL (72.40 mM) |
| References | 1. Dhurandhar R W , Teasdale S J , Mahon W A . Bretylium Tosylate in the Management of Refractory Ventricular Fibrillation[J]. Canadian Medical Association journal, 1971, 105(2):161-5 passim. 2. Heissenbuttel R H , Bigger J T . New Drugs: Bretylium Tosylate: A Newly Available Antiarrhythmic Drug for Ventricular Arrhythmias[J]. Annals of internal medicine, 1979, 91(2):229-238. |